Nantahala Capital Management, LLC Curis Inc Transaction History

Nantahala Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.51 - $0.78 $288,469 - $441,189	-565,627 Reduced 71.04%	230,614 $138,000
Q4 2022 Feb 14, 2023	SELL	$0.47 - $17.22 $1.23 Million - $45.2 Million	-2,624,269 Reduced 76.72%	796,241 $437,000
Q3 2022 Nov 10, 2022	SELL	$0.74 - $15.01 $153,662 - $3.12 Million	-207,652 Reduced 5.72%	3,420,510 $2.43 Million
Q2 2022 Aug 15, 2022	BUY	$0.71 - $2.43 $816,426 - $2.79 Million	1,149,897 Added 46.4%	3,628,162 $3.57 Million
Q1 2022 May 13, 2022	BUY	$2.31 - $5.13 $199,985 - $444,124	86,574 Added 3.62%	2,478,265 $5.9 Million
Q4 2021 Feb 14, 2022	SELL	$4.45 - $8.09 $313,978 - $570,806	-70,557 Reduced 2.87%	2,391,691 $11.4 Million
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $2.63 Million - $3.35 Million	378,712 Added 18.18%	2,462,248 $19.3 Million
Q2 2021 Aug 16, 2021	BUY	$7.45 - $16.27 $3.14 Million - $6.85 Million	420,825 Added 25.31%	2,083,536 $16.8 Million
Q1 2021 May 14, 2021	BUY	$8.78 - $12.8 $261,608 - $381,388	29,796 Added 1.82%	1,662,711 $18.8 Million
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $1.76 Million - $13.4 Million	1,632,915 New	1,632,915 $13.4 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.